Science
Dupixent® (Dupilumab) Approved In The European Union As The First And Only Medicine For Young Children With Eosinophilic Esophagitis
(MENAFN - GlobeNewsWire - Nasdaq) Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to ...
By: menafn
- Nov 06 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS